# Who are LigaChem Biosciences's customers? Who does LigaChem Biosciences earn revenue from?
Canonical: https://valuechain.wiki/ligachem-biosciences · Facet: customers · Updated: 2026-09-04T23:10:43.505657+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: LigaChem Biosciences's confirmed revenue counterparties include 얀센 바이오테크 / 존슨앤드존슨 (LCB84 Trop2-ADC), Amgen plus 3 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 5 revenue edges, backed by 8 dated sources, 5 of them primary filings (as of 2026-09-04).

### 얀센 바이오테크 / 존슨앤드존슨 (LCB84 Trop2-ADC) (high)  → /johnson-johnson.md
- metric: Amount $1.7B · LCB84 총 계약규모(마일스톤 포함)
- note: In Dec 2023 out-licensed worldwide exclusive rights to the Trop2 ADC candidate LCB84 to Janssen (J&J): up to USD 1.7225bn (USD 100m upfront + USD 200m option + USD 1,422.5m milestones) plus tiered royalties on net sales.
- [mentions] AJU Business Daily (KO, research, published 2025-12-22) https://www.ajunews.com/view/20251222092821624: "Hyundai Motor Securities raised its target to KRW 240,000 (+60%) on LCB84 indication expansion and platform value."
- [confirms] DART (FSS) (KO, filing, published 2023-12-26) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20231226900002: "Counterparty: Janssen Biotech, Inc.; total up to USD 1,722,500,000 (KRW 2.246tn) plus royalty — USD 100m upfront, USD 200m option, USD 1,422.5m milestones."
- [confirms] The Korea Economic Daily (KED Global) (EN, news, published 2023-12-26) https://www.kedglobal.com/bio-pharma/newsView/ked202312260001: "LegoChem Bio and Janssen sign an ADC licensing deal worth up to USD 1.7bn."
- [mentions] Business Wire (EN, news, published 2023-12-25) https://www.businesswire.com/news/home/20231225841872/en/: "LCB84 applies LigaChem's next-gen ADC platform and a Trop2 antibody licensed from Mediterranea Theranostic; in a Phase 1/2 US trial."

### 오노약품공업 (LCB97 L1CAM-ADC + ADC 플랫폼) (high)
- metric: Amount $700M · LCB97 총 계약규모
- note: In Oct 2024 out-licensed worldwide exclusive rights to the L1CAM ADC LCB97 to Ono Pharmaceutical (Japan) for USD 700m (~KRW 943.5bn) plus royalties, and on the same day signed a separate multi-target ADC platform deal (undisclosed value).
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "In Oct 2024 signed two transfers with Ono Pharmaceutical covering LCB97 (L1CAM-ADC) and the ADC platform."
- [confirms] DART (FSS) (KO, filing, published 2024-10-10) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20241010900213: "Counterparty: Ono Pharmaceutical (Japan); total USD 700,000,000 (KRW 943.46bn) plus royalties for worldwide exclusive rights to LCB97 (L1CAM-ADC)."
- [confirms] DART (FSS) (KO, filing, published 2024-10-10) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20241010900215: "Counterparty: Ono Pharmaceutical; subject: multi-target ADC platform (site-specific conjugation, linker, payload); total undisclosed."

### 오리온그룹 / PAN Orion Corp. (high)  → /orion.md
- metric: Market share 25.58% · 최대주주 지분율
- note: PAN Orion Corp. Limited, the Orion Group's investment vehicle, became the largest shareholder on 29 Mar 2024 with a 25.58% stake.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "Largest shareholder PAN Orion Corp. Limited, 25.58% stake, newly acquired 29 Mar 2024."

### 시스톤(CStone) (LCB71 ROR1-ADC) (mid)
- metric: Amount $364M · LCB71 총 계약규모
- note: Out-licensed the ROR1 ADC LCB71 (CS5001) to China's CStone: USD 363.5m (upfront + milestones) plus royalties and revenue sharing; Phase 1 ongoing in the US, Australia and China.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "CS5001 (LCB71, ROR1-ADC) licensed to China's CStone, Phase 1 in US/Australia/China; ROR1-ADC total USD 363.5m (upfront + milestones) plus royalty."

### 포순제약(Fosun Pharma) (LCB14 HER2-ADC) (mid)
- metric: Amount $4M · LCB14 임상3상 진입 마일스톤
- note: Licensed the HER2 ADC LCB14 (Caxmotabart Entudotin) to China's Fosun Pharma for the China market (~KRW 20.9bn); received a USD 3.5m (~KRW 4.55bn) Phase 3-entry milestone in Apr 2023.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "LCB14 (HER2-ADC) licensed to Fosun Pharma for the China market; ~KRW 20.9bn (upfront + milestone) plus royalty."
- [confirms] DART (FSS) (KO, filing, published 2023-04-03) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20230403900238: "LCB14, licensed to China's Fosun Pharma, triggered a USD 3,509,446.98 (~KRW 4.55bn) milestone on Phase 3 entry."

### 암젠 (mid)  → /amgen.md
- note: In Dec 2022 signed an ADC platform (source-technology) transfer deal with US-based Amgen; part of the ~KRW 9.4tn disclosed cumulative drug-segment milestones.
- [confirms] DART (FSS) (KO, filing, published 2026-03-23) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260323001538: "Dec 2022: ADC platform transfer deal with Amgen; disclosed drug-segment milestones total ~KRW 9.4tn."

Reverse side: https://valuechain.wiki/ligachem-biosciences/suppliers.md · Ripple: https://valuechain.wiki/ligachem-biosciences/ripple.md

---
Full node: https://valuechain.wiki/ligachem-biosciences.md · JSON: https://valuechain.wiki/ligachem-biosciences.json